Molecular mechanisms that confer antibacterial drug resistance

Nature

Volumn 406, Issue 6797, 2000, Pages 775-781

  Walsh, Christopher ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; BACTERIAL INFECTION; DRUG MECHANISM; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MICROBIAL; HUMANS;

BACTERIA (MICROORGANISMS); EUKARYOTA;

EID: 0034680167     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/35021219     Document Type: Review

References (64)

1. Neu, H. C. The crisis in antibiotic resistance. Science 257, 1064-1073 (1992).
2. Gold, H. S. & Moellering, R. C. Antimicrobial-drug resistance. N. Engl. J. Med. 335, 144-1453 (1996).
3. Levy, S. B. The challenge of antibiotic resistance. Sci. Am. 275, 46-53 (1998).
4. Levy, S. B. Multidrug resistance - a sign of the times. N. Engl. J. Med. 338, 1376-1378 (1998).
5. Spratt, B. G. & Cromie, K. D. Rev. Infect. Dis. 10, 699 (1988).
6. Williams, D. H. The glycopeptide story - how to kill the deadly "superbugs". Nat. Prod. Rep. 13, 469-177 (1996).
7. Brisson-Noel, A., Trieu-Cuot, P. & Courvalin, P. Mechanism of action of spiramycin and other macrolides. J. Antimicrob. Chemother. 22(Suppl. B), 13-23 (1988).
8. Chopra, I. in The Tetracyclines, Handbook of Experimental Pharmacology Vol 78 (eds Hlavaka, J. J. & Boothe, I. H.) 317-392 (Springer, Berlin, 1985).
9. Fourmy, D., Recht, M. I., Blanchard, S. C. & Puglisi, J. D. Structure of the A site of the Esherichia coli 16S ribosomal RNA complexed with an aminoglycoside antibiotic. Science 274, 1371-1376 (1996).
10. Kloss, P., Xiong, I., Shinabarger, D. I., & Mankin, A. S. Resistance of mutations in 23S rRNA identify the site of action of the protein synthesis inhibitor linezolid in the ribosomal peptidyl transferase center. J. Mol. Biol. 294, 93-101 (1999).
11. Shen, L. L. in Quinolone Antibacterial Agents, 2nd edn (eds Hooper, D. C. & Wolfson, J. S.) 77 (American Society for Microbiology, Washington DC, 1993).
12. Maxwell, A. DNA gyrase as a drug target. Trends Microbiol. 5, 102-109 (1997).
13. Ferrero, L., Cameron, B. & Crouzet, J. Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutant of Staphylococcus aureus. Antimicrob. Agents Chemother. 39, 1554-1558 (1995).
14. Davies, J. Bacteria on the rampage. Nature 383, 219-220 (1996).
15. Murray, E. Vancomycin resistant enterococci. Am. J. Med. 102, 284-293 (1997).
16. Arthur, M. & Courvalin, P. Genetics and mechanisms of glycopeptide resistance in enterococci. Antimicrob. Agents Chemother. 37, 1563-1571 (1993).
17. Walsh, C, Fisher, S. L., Park, I. S., Prahalad, M. & Wu, Z. Bacterial resistance to vancomycin: five genes and one missing hydrogen bond tell the story. Chem. Biol. 3, 21-28 (1996).
18. Davies, J. Inactivation of antibiotics and the dissemination of resistance genes. Science 264, 375-382 (1994).
19. Schentag, J.J. et al. Genesis of methicillin resistant Staphylacoccus aureus (MRSA). Clin. Infect. Dis. 26, 1204-1212 (1998).
20. Jacoby, G. A. & Archer, G. L. New mechanisms of resistance to antibacterial agents. N. Engl. J. Med. 324, 601-612 (1991).
21. Levy, S. B. Active efflux mechanisms for antimicrobial resistance. Antimicrob. Agents Chemother. 36, 695-703 (1992).
22. Paulsen, I. T., Brown, M. H. & Skurray, R. A. Proton-dependent multidrug efflux systems. Microbiol. Rev. 60, 575-608 (1996).
23. Ross, J. et al. Inducible erythromycin resistance in staphylococci is encoded by a member of the ATP-binding transport super gene family. Mol. Microbiol. 4, 1207-1214 (1990).
24. Philippon, A., Labia, R. & Jacoby, G. Extended spectrum beta-lactamases. Antimicrob. Agents Chemother. 28, 302-307 (1985).
25. Shaw, K. J., Rather, P. N., Hare, S. R. & Miller, G. H. Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycoside-modifying enzymes. Microbiol. Rev. 57, 138-163 (1993).
26. Hon, W. C. et al. Structure of an enzyme required for aminoglycoside antibiotic resistance reveals homology to eukaryotic protein kinases. Cell 89, 887-895 (1997).
27. Bussiere, D. et al. Crystal structure of ErmC', an rRNA methyltransferase which mediates antibiotic resistance in bacteria. Biochemistry 37, 7103-7112 (1998).
28. Bugg, T. D. H. et al. Molecular basis for vancomycin resistance in Enteracoccus faecium, BM4147: biosynthesis of a depsipeptide peptidoglycan precursor by vancomycin resistance proteins VanH and VanA. Biochemistry 30, 10408-10415 (1991).
29. Song, M. D., Wachi, M., Doi, M., Ishino, F. & Matsuhashi, M. Evolution of an inducible penicillin target protein in MRSA by gene fusion. FEBS Lett. 221, 167 (1987).
30. Spratt, B. G. Resistance to antibiotics mediated by target alterations. Science 264, 388-393 (1994).
31. Knowles, J. R. Penicillin resistance: the chemistry of beta-lactamase inhibition. Acc. Chem. Res. 18, 97-105 (1985).
32. The choice of antibacterial drugs. Med. Lett. 41, 95-104 (1999).
33. Nelson, M. L., Park, R. H. & Levy, S. B. Molecular requirement for the inhibition of the tetracycline antiport protein and the effect of potent inhibitors on the growth of tetracycline-resistant bacteria. J. Med. Chem. 37, 1355-1361 (1994).
34. Chu, D. W., Plattner, J. J. & Katz, L. New directions in antibacterial research. J. Med. Chem. 39, 3853-3874 (1996).
35. Agouridas, C., Benedetti, Y., Denis, A., Le Martert, O. & Chantot, J. F. Ketolides: a new distinct class of macrolide antibacterials, synthesis and structural characteristics of RU 004. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy Abstr. F158 (American Society for Microbiology, 1995).
36. Biavasco, F. et al. In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide Antimicrob. Agents Chemother. 41, 2165-2172 (1997).
37. Williams, D. H., Maguire, A. J., Tsuzuki, W. & Westwell, M. S. An analysis of the origins of cooperative binding energy of dimerization. Science 280, 711-713 (1998).
38. Ge, M. et al. Vancomycin derivatives that inhibit peptidoglycan biosynthesis without binding D-Ala-D-Ala. Science 284, 507-511 (1999).
39. Walsh, C. Deconstructing vancomycin. Science 284, 442-443 (1999).
40. Barry, A. L. & Fuchs, P. C. In vitro activities of a streptogramin (RP59500), three macrolides, and an azolide against four respiratory tract pathogens. Agents Chemother. 39, 238-240 (1995).
41. Linden, P. K., Pasculle, A. W., McDevitt, D. & Kramer, D. J. Effect of quinupristin/dalfopristin (synercid) treatment of infections caused by vancomycin-resistant Enterococcus faecium (VREF). J. Antimicrob. Chemother. 39(Suppl. A), 145-151 (1997).
42. Chien, J. W., Kucia, M. L. & Salata, R. A. Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections. Clin. Infect. Dis. 30, 146-151 (2000).
43. Kurz, M. & Guba, W. 3D structure of ramoplanin: a potent inhibitor of bacterial cell wall biosynthesis. Biochemistry 35, 12570-12575 (1996).
44. Chapra, I., Hodgson, J., Metcalf, B. & Poste, G. The search for antimicrobial agents effective against bacteria resistant to multiple antibiotics. Antimicrob. Agents Chemother. 41, 497-503 (1997).
45. Chan, M. K. et al. Crystal structure of E. coli peptide deformylase. Biochemistry 36, 13904-13909 (1997).
46. Chen, D. Z. et al. Actinonin, a naturally occurring antibacterial agent is a potent peptide deformylase inhibitor. Biochemistry 39, 1256-1262 (2000).
47. Barret, J. F. & Isaacson, R. F. Bacterial virulence as a potential target for therapeutic intervention. Annu. Rep. Med. Chem. 30, 111-118 (1995).
48. Stephens, C. & Shapiro, L. Bacterial protein secretion - a target for new antibiotics? Chem. Biol. 4, 637-641 (1997).
49. Barret, J. F. & Hoch, J. A. Two-component signal transduction as a target for microbial anti-infective therapy. Antimicrob. Agents Chemother. 42, 1529-1536 (1998).
50. Kleerebezem, M., Quadri, L. E. N., Kuipers, O. P. & de Vos, W. M. Quorum sensing by peptide pheromones and two-component signal-transduction systems in gram-positive bacteria. Mol. Microbiol. 24, 895-904 (1997).
51. Reimmann, C. et al. The global activator gacA of Pseudomonas aeruginosa PAO positively controls the production of the autoinducer N-butyryl-homoserine lactone and the formation of the virulence factors pyocyanin, cyanide, and lipase. Mol. Microbiol. 24, 309-319 (1997).
52. Sofia, M. J. et al. Discovery of novel disaccharide antibacterial agents using a combinatorial library approach. J. Med. Chem. 42, 8194-8198 (1999).
53. Tan, D. S., Foley, M. A., Shair, M. D. & Schreiber, S. L. Stereoselective synthesis of over two million compounds having structural features both reminiscent of natural products and compatible with miniaturized cell-based assays. J. Am. Chem. Soc. 120, 8565-8566 (1998).
54. Leadlay, P. F. Combinatorial approaches to polyketide biosynthesis. Curr. Opin. Chem. Biol. 1, 162-168 (1997).
55. Katz, L. Manipulation of modular polyketide synthases. Chem. Rev. 97, 2557-2575 (1997).
56. Khosla, C. Harnessing the biosynthetic potential of modular polyketide synthases. Chem. Rev. 97, 2577-2590 (1997).
57. Cane, D. E., Walsh, C. T. & Khosla, C. Harnessing the biosynthetic code: combinations, permutations, and mutations. Science 282, 63-68 (1998).
58. McDaniel, R. et al. Multiple genetic modifications of the erythromycin polyketide synthase to produce a library of novel "unnatural" natural products. Proc. Natl Acad. Sci. USA 96, 1846-1851 (1999).
59. Zhao, L. et al. Engineering a methymycin/pikromycin-calicheamicin hybrid: construction of two new macrolides carrying a designed sugar moiety. J. Am. Chem. Soc. 121, 9881-9882 (1999).
60. Schlaes, D.M. et al. Guidelines for the prevention of antimicrobial resistance in hospitals. Clin. Infect. Dis. 25, 583-599 (1997).
61. Waldvogel, F. A. New resistance in Staphylococcus aurens. N. Engl. J. Med. 340, 556-557 (1999).
62. Drugs for HIV infection. Med. Lett. 42, 1-6 (2000).
63. Witte, W. Medical consequences of antibiotic use in agriculture. Science 279, 996-997 (1998).
64. Chow, J. W., Donahedian, S. M. & Zervos, M. J. Emergence of increased resistance to quinupristir/dalfopristin during therapy for Enterococcus faecium bacteremia. Clin. Infect. Dis. 24, 90-91 (1997).